Table 2.

Adverse events related to transfusion of COVID-19 convalescent plasma

First author or trial name	CCP arm, N	Control arm, N	Control	Clinical status: severity of COVID-19	Transfusion-related adverse events	Mortality related to transfusion of CCP
PLACID Trial19	227	224	Standard of care	Moderate WHO scale 4-5	3 transfusion-related events with CCP	3 deaths reported as possibly related to transfusion of CCP
AlQahtani20	20	20	Standard of care	Moderate WHO scale 4-6	No transfusion-related events reported	N/A
Avendano-Sola31	38	43	Standard of care	Moderate WHO scale 4-6	2 transfusion-related events with CCP	N/A
CONCOR-1 Study Group13	614	307	Standard of care	Moderate to severe WHO scale 4-6	35 transfusion-related events in the CCP cohort: 4 were life-threatening (2 TACO, I possible TRALI, 1 TAD)	N/A
Bennet-Guerrerro21	59	15	Nonimmune plasma	Moderate to severe WHO scale 4-7*	1 transfusion-related event in CCP group and 0 in control group	N/A
REMAP-CAP Investigators26	1084	916	Standard of care	Moderate to severe WHO scale 4-7*	32/1075 (3.0%) with ≥ 1 serious adverse event in the CCP group vs 12/905 (1.3%) in the control group	N/A
Gharbharan22	43	43	Standard of care	Moderate to severe WHO scale 4-7*	No SAEs reported with CCP	N/A
Hamdy30	15	15	Standard of care	Moderate to severe WHO scale 4-6	No transfusion-related events reported	N/A
RECOVERY Trial26	5795	5763	Standard of care	Moderate to severe WHO scale 4-7*	13 transfusion-related events in CCP cohort reported to SHOT: 9 pulmonary reactions (not TRALI); 4 serious febrile, allergic or hypotensive reactions; 16 severe allergic reactions reported within 72 h of randomization in CCP cohort and 2 in control group.	3 deaths reported in CCP cohort that may have been related to transfusion
Kirenga27	69	67	Standard of care	Moderate to severe WHO scale 4-6	3 adverse events were judged definitively related, and 3 were judged possibly related to plasma transfusion.
SIREN-C3PO Investigators35	257	254	Normal saline	Mild WHO scale 2-3	Transfusion-related adverse events occurred more frequently in CCP arm and dyspnea was more frequent in placebo arm.	N/A
CAPSID Trial28	53	52	Standard of care	Moderate to severe WHO scale 4-7	No significant difference was seen in the frequency or grade of adverse events when comparing the CCP and standard of care arms.	N/A
Li23	52	51	Standard of care	Moderate to severe WHO scale 4-7*	2 transfusion-related events with CCP	N/A
Libster33	80	80	Normal saline	Asymptomatic to mild WHO scale 1-2	No transfusion-related events reported in CCP or control cohorts.	N/A
O’Donnell24	150	73	Nonimmune plasma	Moderate to severe WHO scale 4-9	4 events definitely or probably related to transfusion occurred in CCP cohort; 3 events definitely or probably related to transfusion occurred in control group	N/A
PlasmAr Study Group29	228	105	Normal Saline	Moderate to severe WHO scale 4-6	11 transfusion-related events reported for CCP cohort; 2 transfusion-related events reported in control group	N/A
Joyner50	20 000	N/A	N/A	Moderate to severe WHO scale 4-7*	Events reported as possibly or definitely related to transfusion: 36 TACO; 21 TRALI; 21 severe allergic	10 events within 4 h of CCP transfusion, all reported as possibly related

TACO, transfusion-associated circulatory overload; TAD, transfusion-associated dyspnea; TRALI, transfusion-related acute lung injury.

^*Information was not available to distinguish between WHO scale categories 7 and 9.